文献类型：期刊文献

中文题名：依达拉奉右莰醇治疗急性缺血性脑卒中有效性和安全性的Meta分析

英文题名：Efficacy and safety of Edaravone Dexborneol in the treatment of acute ischemic stroke:A Meta-analysis

作者：苏晓洁[1];雷文娟[1];高琲[1];李玉英[2];惠红[1];田敏[1];孟敏[1]

第一作者：苏晓洁

机构：[1]甘肃省人民医院,甘肃兰州730000;[2]甘肃中医药大学药学院,甘肃兰州730000

第一机构：甘肃省人民医院,甘肃兰州730000

年份：2026

卷号：45

期号：3

起止页码：245

中文期刊名：甘肃医药

外文期刊名：Gansu Medical Journal

语种：中文

中文关键词：依达拉奉右莰醇;缺血性脑卒中;有效性;安全性;Meta分析

外文关键词：Edaravone Dexborneol;acute ischemic stroke;efficacy;safety;Meta-analysis

摘要：目的:评价依达拉奉右莰醇治疗急性缺血性脑卒中的有效性和安全性。方法:系统检索Medline(via PubMed)、Embase、Cochrane Library、CNKI、万方和CBM数据库,检索截止时间为2023年11月15日,按照纳入与排除标准,纳入对症治疗(对照组)联合依达拉奉右莰醇(试验组)治疗急性缺血性脑卒中患者的随机对照试验,并进行数据提取。采用ROB工具进行偏倚风险的评价,使用RevMan5.2软件进行Meta分析。结果:共纳入17项RCT,包含1822例患者,其中试验组909例,对照组913例。Meta分析结果显示,与对照组相比,依达拉奉右莰可提高急性缺血性脑卒中患者的临床有效率OR=4.20,95%CI(3.12,5.65)(P<0.05),且两组之间的不良反应差异无统计学意义[OR=0.81,95%CI(0.57,1.15),P>0.05]。依达拉奉右莰醇组14 d美国国立卫生研究院卒中量表评分(NHISS)、改良Rankin评分(mRS)、C反应蛋白(CRP)、基质金属蛋白酶-9(MMP-9)优于对照组[MD=-2.55,95%CI(-3.25,-1.85),P<0.05;MD=-0.40,95%CI(-0.59,-0.22),P<0.05;MD=-2.41,95%CI(-3.10,-1.73),P<0.05;MD=-26.18,95%CI(-31.38,-20.97),P<0.05]。结论:联合使用依达拉奉右莰醇治疗急性缺血性脑卒中有较好的疗效,且无显著的不良反应,可作为一种神经保护剂在治疗急性缺血性脑卒中患者中推广使用。
Objective:To systematically review the efficacy and safety of Edaravone Dexborneol in the treatment of acute ischemic stroke.Methods:The randomized controlled trial(RCT)for the treatment of acute ischemic stroke with symptomatic treatment(control group)plus Edaravone Dexborneol(trial group)were searched Medline(via Pubmed),Embase,Cochrane Library,CNKI,Wanfang and CBM databases with a search deadline of 15 November 2023 and data extraction was performed.The risk of bias of the included studies was evaluated using the Cochrane assessment tool,and Meta-analysis was performed using RevMan 5.2 software.Results:A total of 17 RCTs containing 1822 patients were included,including 909 patients in the experimental group and 913 patients in the control group.Meta-analysis showed that Edaravone Dexborneol increased the clinical efficacy rate of patients with AIS when compared with the control group[OR=4.20,95%CI(3.12,5.65),P<0.05],and there was no statistically significant difference of adverse effects between the two groups[OR=0.81,95%CI(0.57,1.15),P>0.05].The 14-d National Institutes of Health Stroke Scale score(NHISS),modified Rankin score(mRS),C-reactive protein(CRP),and matrix metalloproteinases-9(MMP-9)in the Edaravone Dexborneol group were significantly better than those in the control group[MD=-2.55,95%CI(-3.25,-1.85),P<0.05];[MD=-0.40,95%CI(-0.59,-0.22),P<0.05];[MD=-2.41,95%CI(-3.10,-1.73),P<0.05;MD=-26.18,95%CI(-31.38,-20.97),P<0.05].Conclusion:The combined use of Edaravone Dexborneol in the treatment of AIS has good efficacy and no significant adverse effects,and can be promoted as a neuroprotective agent in the treatment of AIS.